Engineered immune cells take aim at Hard-to-Treat ovarian cancer

This early-stage study tests a new treatment for people with ovarian cancer that has come back. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack a protein (FSHR) found on cancer cells. The main goal is to check the safety of these cells and find the best dose, with or without chemotherapy before the infusion. Ten adults with recurrent ovarian, fallopian tube, or peritoneal cancer will take part.